How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,936 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Squamous cell carcinoma of the skin

Squamous cell carcinoma of the skin Squamous cell carcinoma of the skin - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Squamous cell carcinoma of the skin Last reviewed: February 2019 Last updated: August 2018 Summary Malignant tumour of keratinocytes arising in the epidermis of the skin. Second most common non-melanoma skin cancer worldwide, secondary to basal cell carcinoma. Cumulative ultraviolet exposure, most (...) commonly from the sun, and immunosuppression are major risk factors. Treatments include non-surgical destruction (e.g., using cryotherapy), topical chemotherapy, traditional surgical excision, and Mohs micrographic surgery. Definition Cutaneous squamous cell carcinoma (SCC) is the proliferation of atypical, transformed keratinocytes in the skin with malignant behaviour. It ranges from in situ tumours (also known as Bowen's disease) to invasive tumours and metastatic disease. [Figure caption

2018 BMJ Best Practice

2. Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin

Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin Comparative Effectiveness Review Number 199 Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin Evidence Summary Introduction Skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common malignancies in the United States. 1 BCC and SCC, the 2 most common skin cancers, are collectively referred to as keratinocyte carcinomas. Over 5.4 million of these lesions are diagnosed (...) in square brackets. RoB = risk of bias; BCC = basal cell carcinoma; SCCIS = squamous cell carcinoma in situ; MMS = Mohs micrographic surgery; PDT = photodynamic therapy; RCT = randomized controlled trial; NRCS = nonrandomized comparative study; CI = confidence interval Table E. Summary conclusions for SCCIS lesions and strength of the relevant evidence (continued)References 1. Centers for Disease Control and Prevention Skin Cancer Statistics. 2015. http://www.cdc.gov/cancer/skin/statistics/index. htm. 2

2017 Effective Health Care Program (AHRQ)

3. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma Cemiplimab for treating metastatic or Cemiplimab for treating metastatic or locally advanced cutaneous squamous locally advanced cutaneous squamous cell carcinoma cell carcinoma T echnology appraisal guidance Published: 7 August 2019 www.nice.org.uk/guidance/ta592 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms? (PubMed)

Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms? Second primary cancers (SPCs) are becoming a common cancer entity, which may interfere with survival in relatively benign first primary cancers. We examined the hypothesis that immune dysfunction may contribute to SPCs by assessing SPCs associated with known immune responsive skin cancers, invasive and in situ squamous cell carcinoma (...) , Kaposi sarcoma, and Merkel cell carcinoma. Cancers were identified from the Swedish Cancer Registry from the year 1958 to 2015. Standardized relative risks were calculated bidirectionally for any SPC after skin cancer and for skin cancer as SPC. Over 80,000 first primary cancers were identified for each invasive and in situ squamous cell carcinoma of the skin. Bidirectional increased risks were observed for 26 cancers associated with invasive skin cancer; the Spearman rank correlation was 0.72 (P

2019 Journal of Investigative Dermatology

5. Cemiplimab (Libtayo) - cutaneous squamous cell carcinoma

and why it is authorised in the EU What is Libtayo and what is it used for? Libtayo is a cancer medicine used on its own to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). It is used in patients who cannot have surgery or treatment with radiation to cure their disease. Libtayo contains the active substance cemiplimab. How is Libtayo used? Treatment (...) (life-threatening reactions with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals) have been reported with Libtayo. For the full list of side effects and restrictions with Libtayo, see the package leaflet. Why is Libtayo authorised in the EU? Libtayo is effective at treating cutaneous squamous cell carcinoma, a cancer with few treatment options once it has spread. However, the study involved a small number of patients and additional data are required

2019 European Medicines Agency - EPARs

6. Comparison of P53 Intensity, Frequency and Size in Normal Skin Periphery of Squamous Cell Carcinoma, Basal Cell Carcinoma And Melanocytic Nevus in Persian Skin Type (PubMed)

Comparison of P53 Intensity, Frequency and Size in Normal Skin Periphery of Squamous Cell Carcinoma, Basal Cell Carcinoma And Melanocytic Nevus in Persian Skin Type Non-Melanoma Skin Cancer (NMSC), the most prevalent types being Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC), is the most common type of malignancy in human beings. These neoplasms are more frequent in the elderly and fair skinned people and mainly occur on sun-exposed sites of the body. Ultraviolet B (UVB) has (...) a well-known effect in induction and promotion of growth of these cancers. The p53 tumor suppressor gene is believed to be an early target in UV-induced skin carcinogenesis. Aggregates of keratinocytes with p53 protein overexpression are frequently identified in normal human skin and are more prevalent in chronically sun-exposed skin, and have been proposed to play a role in skin cancer pathogenesis. The aim of this study was to clarify the potential role of P53 in the development

Full Text available with Trip Pro

2017 Iranian Journal of Pathology

7. Sun protection for preventing basal cell and squamous cell skin cancers. (PubMed)

Sun protection for preventing basal cell and squamous cell skin cancers. 'Keratinocyte cancer' is now the preferred term for the most commonly identified skin cancers basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), which were previously commonly categorised as non-melanoma skin cancers (NMSC). Keratinocyte cancer (KC) represents about 95% of malignant skin tumours. Lifestyle changes have led to increased exposure to the sun, which has, in turn, led to a significant (...) and barrier methods) for preventing keratinocyte cancer (that is, basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) of the skin) in the general population.We searched the following databases up to May 2016: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trial registries and the bibliographies of included studies for further references to relevant trials.We included randomised controlled clinical trials (RCTs) of preventive

2016 Cochrane

8. Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. (PubMed)

Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. Koebnerized non-melanoma skin cancer following skin trauma represents a rare and obscure event.To study molecular pathological parameters in koebnerized squamous cell carcinomas (K-SCCs) occurring after complete tumour removal.We assessed two patients with multiple sclerosis who were on treatment with dimethylfumarate (DMF) preceded (...) by long-term azathioprine therapy. Both patients rapidly developed several K-SCCs following histopathologically proven complete excision of cutaneous SCCs. We performed immunohistochemistry for p53, p16, Ki-67, TET-2, IDH-2, 5-hmc and 5-mc. PCR was carried out for the detection of human papilloma viruses. Mutation analysis was performed for BRAF, K-RAS and EGFR.All lesions investigated were negative for HPV DNA. Mutations were not detected. Healthy appearing skin of both patients showed relatively

2018 Journal of the European Academy of Dermatology and Venereology

9. Reply to Gambichler T et al.: Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. (PubMed)

Reply to Gambichler T et al.: Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. 29797668 2019 01 18 1468-3083 33 1 2019 Jan Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Reply to Gambichler T et al.: Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell (...) carcinomas following skin surgery. e3-e4 10.1111/jdv.15084 Nwabudike L C LC N. Paulescu Institute, Bucharest, Romania. Tatu A L AL Medical and Pharmaceutical Research Unit/Competitive, Interdisciplinary Research Integrated Platform "Dunărea de Jos", ReForm-UDJG, Dermatology, Faculty of Medicine and Pharmacy, Pharmacology Sciences Department, University "Dunarea de Jos", Galati, Romania. eng Letter 2018 06 07 England J Eur Acad Dermatol Venereol 9216037 0926-9959 2018 5 26 6 0 2018 5 26 6 0 2018 5 26 6 0

2018 Journal of the European Academy of Dermatology and Venereology

10. Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report (PubMed)

Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report 29556584 2018 11 14 2452-1094 3 1 2018 Jan-Mar Advances in radiation oncology Adv Radiat Oncol Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report. 76-80 10.1016/j.adro.2017.09.006 Cerra-Franco Alberto A Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana

Full Text available with Trip Pro

2017 Advances in radiation oncology

11. A systematic review of oral skin cancer prophylaxis: the impact of Acitretin on the occurrence of basal and squamous cell carcinoma

A systematic review of oral skin cancer prophylaxis: the impact of Acitretin on the occurrence of basal and squamous cell carcinoma Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units

2019 PROSPERO

12. Alterations of the Human Skin N- and O-Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma (PubMed)

Alterations of the Human Skin N- and O-Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma The glycome of one of the largest and most exposed human organs, the skin, as well as glycan changes associated with non-melanoma skin cancers have not been studied in detail to date. Skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most frequent types of cancers with rising incidence rates in the aging population. We investigated the healthy human (...) skin N- and O-glycome and its changes associated with BCC and SCC. Matched patient samples were obtained from frozen biopsy and formalin-fixed paraffin-embedded tissue samples for glycomics analyses using two complementary glycomics approaches: porous graphitized carbon nano-liquid chromatography electro spray ionization tandem mass spectrometry and capillary gel electrophoresis with laser induced fluorescence detection. The human skin N-glycome is dominated by complex type N-glycans that exhibit

Full Text available with Trip Pro

2018 Frontiers in oncology

13. Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details

Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details | CADTH.ca Find the information you need Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details Project Number pCODR 10187 Brand Name Libtayo Generic Name Cemiplimab Strength 50mg/mL Tumour Type Skin & Melanoma Indication Cutaneous Squamous Cell Carcinoma Funding Request (...) For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Review Status Under Review Pre Noc Submission No NOC Date April 10, 2019 Manufacturer Sanofi Genzyme Sponsor Sanofi Genzyme Submission Date July 9, 2019 Submission Deemed Complete July 30, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ July 23, 2019 Check-point meeting September 17, 2019 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

14. Total body skin examination increases squamous cell carcinoma detection: a retrospective cohort study. (PubMed)

Total body skin examination increases squamous cell carcinoma detection: a retrospective cohort study. Squamous cell carcinomas (SCCs) have the potential for local tissue destruction and metastasis. The risk of complications increases if the lesion is not diagnosed and excised in a timely manner. Total body skin examination (TBSE) has been reported to increase melanoma detection; the objective of this study was to determine if it also increases SCC detection. Analysis of 469 SCCs diagnosed (...) at a UK tertiary centre showed that 6.8% of these were detected incidentally and not from the index lesion that prompted referral. These incidentally detected SCCs tended to represent early disease, and therefore carried lower risk of complications. Our findings suggest that full skin checks may increase the number of SCCs detected, and at an earlier stage of disease. Therefore, we encourage the use of TBSE in all dermatology outpatient appointments, and make suggestions as to how to incorporate

2019 Clinical & Experimental Dermatology

15. Usefulness of real-time elastography for diagnosing lymph node metastasis of skin cancer; does elastography potentially eliminate the need for sentinel lymph node biopsy in squamous cell carcinoma? (PubMed)

Usefulness of real-time elastography for diagnosing lymph node metastasis of skin cancer; does elastography potentially eliminate the need for sentinel lymph node biopsy in squamous cell carcinoma? The metastatic involvement of regional lymph nodes is the most important prognostic factor for overall survival of skin cancer patients. The sonographic technique of freehand real-time tissue elastography (RTE), which displays tissue rigidity as a color overlay of the tissue image, was developed.Our (...) purpose was to evaluate the benefit of RTE for detecting lymph node metastases of skin cancer noninvasively before operation.We first selected lymph nodes of skin cancer patients which had already been diagnosed by biopsy as being reactive or metastatic, and then retrospectively collected images of RTE and B-mode and color Doppler ultrasound on those lymph nodes performed preoperatively. Twenty-one lymph nodes from 12 patients with squamous cell carcinoma (SCC), 23 lymph nodes from 14 patients

2019 Journal of the European Academy of Dermatology and Venereology

16. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. (PubMed)

Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. Early accurate detection of all skin cancer types is essential to guide appropriate management, reduce morbidity and improve survival. Basal cell carcinoma (BCC) is usually localised to the skin but has potential to infiltrate and damage surrounding tissue, while cutaneous squamous cell carcinoma (cSCC) and melanoma have a much higher potential to metastasise and ultimately lead to death. Exfoliative (...) scrape can never give the same information as a skin biopsy, however, so it is important to better understand in which skin cancer situations it may be helpful.To determine the diagnostic accuracy of exfoliative cytology for detecting basal cell carcinoma (BCC) in adults, and to compare its accuracy with that of standard diagnostic practice (visual inspection with or without dermoscopy). Secondary objectives were: to determine the diagnostic accuracy of exfoliative cytology for detecting cSCC

2018 Cochrane

17. Risks of different skin tumor combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population based cohorts: 1989 - 2009. (PubMed)

Risks of different skin tumor combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population based cohorts: 1989 - 2009. Skin cancer patients are primarily at increased risk of developing subsequent skin cancers of the same type. Shared risk factors might also increase the occurrence of a different type of subsequent skin cancer.To investigate risks of different skin tumour combinations after a first melanoma, squamous cell carcinoma (SCC) and basal (...) cell carcinoma (BCC).All melanoma and SCC patients included in the national Netherlands Cancer Registry (NCR) and all BCC patients included in the regional Eindhoven Cancer Registry (ECR) between 1989 and 2009 were followed until diagnosis of a subsequent different skin cancer (melanoma, SCC or BCC), date of death or end of study. Cumulative risks, standardized incidence ratios (SIR) and absolute excess risks (AER) of subsequent skin cancers were calculated.A total of 50 510 melanoma patients

Full Text available with Trip Pro

2017 Journal of the European Academy of Dermatology and Venereology

18. Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice (PubMed)

Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice Targeted immunotherapy using dendritic cell vaccine has been employed for the treatment of solid tumors. Topical 5-aminolevulinic acid-mediated photodynamic therapy, an established approach for topical cancers, can induce an effective antitumor immune response. We have previously shown that 5-aminolevulinic acid-mediated photodynamic therapy-induced tumor lysates could (...) considerably enhance antigen-presenting capacity of ex vivo-generated dendritic cells. The current study further demonstrates that 5-aminolevulinic acid-mediated photodynamic therapy dendritic cell vaccine can induce immune responses against cancers. Dendritic cells pulsed by photodynamic therapy-treated skin squamous cell carcinoma cells inhibited squamous cell carcinoma to a greater extent than tumor lysates treated by photodynamic therapy alone or dendritic cells pulsed by freeze-thawed treated tumor

Full Text available with Trip Pro

2018 Technology in cancer research & treatment

19. Finger Pad Squamous Cell Carcinoma: Report of Squamous Cell Carcinoma of the Distal Palmar Digit and Review of Associated Risk Factors, Mimickers, and Treatment of Squamous Cell Carcinoma of Ventral Hand Digits (PubMed)

of the hand. the authors also summarize the clinical differential diagnoses and treatment of squamous cell carcinoma at this location. METHODS: the authors retrospectively reviewed the literature using PubMed and searched for the following terms: squamous cell carcinoma, squamous cell carcinoma in situ, finger, thumb, palmar, and ventral. Papers were critically evaluated and their cited references reviewed. RESULTS: Skin biopsy established the patient's diagnosis. His tumor was excised using Mohs (...) Finger Pad Squamous Cell Carcinoma: Report of Squamous Cell Carcinoma of the Distal Palmar Digit and Review of Associated Risk Factors, Mimickers, and Treatment of Squamous Cell Carcinoma of Ventral Hand Digits BACKGROUND: Squamous cell carcinoma of the palmar digits is rare. PURPOSE: The authors describe a man with squamous cell carcinoma of the pulp of his left fourth finger, and review the risk factors that may be associated with squamous cell carcinoma development on the ventral digits

Full Text available with Trip Pro

2017 The Journal of clinical and aesthetic dermatology

20. Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma

Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>